(702) 683-8946

Monday - Friday 9am to 5pm

triangle
ad1

http://crweworld.com/assets/images/ad/content-delivery-solution.jpg

Our content delivery solution through CRWE WORLDCRWE Press Release and CRWE Tubegives corporations and businesses a vehicle to expand their exposure

Content Delivery Solution (Learn More)

ad3

http://crweworld.com/assets/img/crwe_info.png

CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform

www.crwe.info

ad4

http://crweworld.com/assets/images/ad/submit_a_press_release.jpg

Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business

www.CRWEPressRelease.com






Corporate Earnings, Revised Guidance, and Medical Breakthroughs: Insights on Hibbett, Booz Allen Hamilton, and Novo Nordisk

  • May 26th, 2023
  • 328 views

Hibbett, Inc. (Nasdaq: HIBB) released its first-quarter fiscal 2024 earnings per share (EPS) of $2.74, falling short of the consensus estimate of $3.04. 

The company revised its full-year fiscal 2024 guidance to reflect a more cautious consumer outlook. The updated guidance now indicates a diluted EPS range of $7.00 to $7.75, compared to the previous guidance range of $9.50 to $10.00. 

As a result of this news, $HIBB's pre-market trading shows a decline of $4.03 (-9.13%), with the stock currently trading at $40.13.

Booz Allen Hamilton Holding Corporation (NYSE: BAH) reported adjusted EPS of $1.01 for the fourth quarter of fiscal year 2023, surpassing the consensus estimate of $0.95. 

$BAH is experiencing a positive trend in pre-market with an increase of $3.15 (+3.51%), currently trading at $93.00.

Novo Nordisk A/S (NYSE: NVO) has received positive news regarding its once-weekly prescription human growth hormone analog, Sogroya (somapacitan) injection. The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion for the expanded use of Sogroya in children and adolescents with growth hormone deficiency. This rare disease is a treatable cause of short stature, and the approval signifies a significant advancement in addressing this medical condition.

It is worth noting that Sogroya was previously approved in the European Union (EU) for the replacement of endogenous growth hormone in adults with growth hormone deficiency (AGHD) in 2021. This potential expanded use in children and adolescents further emphasizes the impact of Sogroya in addressing growth hormone deficiency across different age groups. 

In pre-market,  $NVO is currently trading at $162.95, showing a slight increase of $0.51 (+0.31%)

 

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)

Social Shares

Post Your Comments